Real questions from real people exploring psychedelics.
How female hormones may affect stacking protocols that include psychedelics
What you’ll learn in this post:
Why estrogen directly affects the same serotonin receptors psilocybin activates
What a 2019 brain-scan study revealed about psilocybin intensity — and what it missed
Why can't the field still tell women which direction hormone shifts push the psychedelic experience
How GLP-1 medications like semaglutide may unpredictably alter psilocybin onset
Why most pharmaceutical dosing still defaults to male-normed research
What to tell your facilitator before a session, regardless of what medicine you're taking
What emerging practice (not settled protocol) suggests about timing psychedelic work around your cycle
The short answer is: almost certainly yes. The longer answer is that science hasn’t caught up with women’s reported experiences.
Just as women’s bodies, the way this question has been posed to me varies:
I had a very different experience the week before my period than I did two weeks earlier.
My microdosing felt like it stopped working after I started HRT.
I’m postmenopausal — do protocols designed for cycling women apply to me?
To women, these aren’t niche questions about psychedelics and hormones because our hormones don’t play a niche role in our lives.
With this broad question in mind, I spoke this week with Stephanie Karzon Abrams, who, as a neuropharmacologist and founder of Beyond Consulting, explores the frontiers of psychedelics, neurology, women’s health, integrative medicine, plant medicines, and policy. This post is a prelude to our episode that drops this Tuesday.
Help me support safe psychedelic experiences with thoughtful content and programming— consider becoming a Paid Subscriber. 🙏
What do we actually know about hormones and psychedelics?
Psilocybin works primarily by activating serotonin 5-HT2A receptors in the brain. The intensity of the experience correlates directly with how much psilocin (the active metabolite your body converts psilocybin into) reaches those receptors and how responsive the receptors are. A 2019 brain-scan study found that the intensity of a psilocybin experience tracks directly with two factors: how much of the active compound is in your blood and how many of the brain’s serotonin receptors it actually binds to.
While this study included women, it did not track or control for their menstrual cycles, so we don’t have the complete picture. Estrogen is not just a reproductive hormone. It actively modulates the serotonin system by influencing how serotonin is synthesized, released, and received. A 2024 review in Endocrinology put it plainly: estrogen affects serotonin receptor sensitivity and responsiveness, and those estrogen-serotonin interactions may change how effective psychedelics are across menstrual cycles and life stages. may.
Which means: if your hormone levels shift, the receiving end of the psychedelic experience likely shifts with them. likely.
What the research has not resolved is which direction the shift goes, by how much, and whether high estrogen amplifies or dampens response. Animal studies point in contradictory directions depending on the model, dose, and phase under study. Some preclinical work suggests low-estrogen states produce a stronger psychedelic response. Other work points in the opposite direction..
What don’t we know — and why?
Grace Blest-Hopley, neuroscientist and founder of Hystelica, one of the few researchers actively focused on this intersection, put it cleanly in our previous podcast episode: “We know that the hormonal landscape is going to influence a woman’s psychedelic experience. We don’t exactly know in what direction.”
That uncertainty stems from women and menstrual-cycle variables being systematically excluded from clinical research for decades. The scarcity of studies comparing outcomes between males and females is a structural problem, not a scientific one. The data doesn’t exist because nobody collected it, and this remains a challenge throughout women’s health research more broadly, and psychedelics specifically.
What that means in practice: there are no dosing protocols personalized to cycle phase. There are no established guidelines for how hormonal birth control, surgical menopause, or HRT might shift a psilocybin session. Women on GLP-1 medications like semaglutide face an additional variable — these drugs slow gastric emptying significantly, which can delay and unpredictably alter the onset of oral psilocybin (a prodrug that requires conversion in the gut before it’s active). Retreat clinicians are already seeing this play out with very long onset times and muted effects at doses that would normally be reliable.
Stephanie Karzon Abrams has been doing the methodological work to build protocols that actually account for women’s physiology, because, as she laughingly pointed out in the episode, women are not small men. Medicine has made some progress, but it is nowhere near solved.
Most pharmaceutical dosing still defaults to male-normed research. Women weren’t formally required to be included in clinical trials until the FDA lifted that restriction in 1993, which means decades of approved drugs were dosed based almost entirely on male subjects. The Ambien example is the clearest recent case: women were found to metabolize zolpidem differently, with a higher percentage remaining in the body, and the FDA responded by halving the recommended dose for women specifically. That correction came decades after the drug was already on the market.
A 2022 study found substantial variability in how drug trials reported sex-based differences, and that sources continued to exclude sex-based dosing recommendations even for drugs where sex differences had been documented. Most recently, the FDA released a draft guidance on sex differences in clinical evaluation of medical products in early 2025 — and it was removed from the FDA website shortly after the new administration took office.
What can you do right now?
Track your cycle in relation to your experiences. Women’s lived experience is data. If you notice your microdose lands differently in week one versus week three, write it down. As Grace noted in the episode, women can already tell you, this time of the month, I felt like this. That self-knowledge should be part of every intake conversation.
No matter the specific medicine or dose, tell your psychedelic facilitator what you’re taking. Hormonal contraceptives, HRT, GLP-1 medications, and SSRIs all interact with the systems psychedelics act on. The conversation about onset timing in particular is becoming clinically important as GLP-1 use rises among the same demographic most actively exploring psychedelics.
The following is an emerging practice, not a settled protocol. Some practitioners are beginning to suggest that the late luteal phase (the week before your period) may not be ideal for deeper psychedelic work, while the follicular and ovulatory phases may offer more receptivity.
If you’re postmenopausal or in perimenopause, know that the hormone-serotonin dynamics are different for you than for cycling women, and almost certainly different from the male-majority samples in most existing psychedelic research. There is a distinct lack of data for this life stage, so work with people who know enough to say they don’t know, and track your own experience carefully.
Hormones almost certainly matter to how psychedelics work in women’s bodies. The biological case for that is solid. What the field cannot yet tell you is exactly how, in which direction, or how to personalize your approach with confidence.
In lieu of scientific certainty, Stephanie Karzon Abrams and I are going to dive into Psychedelics & The Whole Self: A Gathering for Womxn next month at Shulgin Farm in Layfayette, CA. This venue holds profound psychedelic history. The Farm is the site of chemist Sasha Shulgin’s lab. Granted a DEA exemption to research Schedule I drugs, Sasha was the first person to synthesize MDMA. His wife Ann authored one of the earliest guidelines on MDMA-assisted psychotherapy.
Space is limited to 50 people, so reserve your spot here. In the meantime, listen to my episode with Dr. Steph Karzon Abrams this Tuesday for more insight into her work focused on The Whole Self.
Take care,
April
Frequently asked questions
Do hormones affect how psilocybin works? Yes, almost certainly. Estrogen actively modulates the serotonin system, including the 5-HT2A receptors that psilocybin acts on. Hormone levels — across the menstrual cycle, perimenopause, and menopause — likely affect how intense and how therapeutic a psilocybin experience is, though the direction and magnitude of that effect has not been established in clinical trials.
Does the menstrual cycle change the psychedelic experience? Research hasn’t directly confirmed this, but the biological rationale is strong. Estrogen influences serotonin receptor sensitivity, and psilocybin intensity correlates with receptor occupancy. Women consistently report variability in their experiences across the cycle. Emerging practitioner guidance suggests the follicular and ovulatory phases may be better suited for deeper psychedelic work than the late luteal phase, though this is practice-based, not clinically proven.
Can women on GLP-1 medications like Ozempic take psilocybin? GLP-1 drugs significantly slow gastric emptying, which can delay and unpredictably alter the onset of oral psilocybin. Retreat clinicians are documenting longer-than-expected onset times and muted effects. Women on semaglutide or tirzepatide should disclose this to their facilitator before any session, and should not redose, assuming the medicine isn’t working.
Does HRT change how psilocybin affects women? There are no established clinical guidelines on how hormone replacement therapy interacts with psilocybin. Given that both estrogen and synthetic progestins affect the serotonin system, it is plausible that HRT changes the experience, but the specific effects have not been studied. Disclosure to your facilitator and careful tracking of your own experience are the best tools currently available.
Why are there no dosing protocols for women in psychedelic research? Women were excluded from most clinical trials until 1993, and menstrual cycle variables have rarely been tracked or controlled for in psychedelic studies since. The result is a field that defaults to male-normed baselines, even as women represent a growing majority of people exploring psilocybin outside clinical settings.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.